What You Should Know:
- Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the capabilities of its Tapestri Platform to become the only commercial solution that delivers simultaneous genotype and targeted gene expression profiling from over 10,000 single cells.
- The assay, which can be leveraged for Phase 2 or 3 trials to home in on patients most likely to
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Oxford Cancer Biomarkers and Mira Precision Health Partner to Advance ToxNav® Cancer Test
What You Should Know:
- Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new partnership with Mira Precision Health Inc.
- This collaboration aims to advance OCB's proprietary ToxNav® test in the United States, a revolutionary precision oncology tool designed to identify patients at high risk of severe toxicity from common chemotherapy treatments.
- Mira Precision Health, headquartered at the Mason 5155 BioHub in
Read More
The NP/PA Factor: Why Advanced Practice Providers Are Essential for Life Sciences in 2025
For decades, life sciences companies have centered their marketing efforts on physicians, assuming they hold the greatest influence over prescribing and treatment decisions. However, the healthcare landscape has shifted dramatically. Nurse practitioners (NPs) and physician assistants/associates (PAs) are not just supporting players, they are primary prescribers shaping patient care across nearly every therapeutic area.
This shift is finally being recognized across the industry. According to
Read More
Kyron.bio Secures $6.2M to Optimize Biologic Drug Development with Precision Glycan Engineering
What You Should Know:
- Biotechnology company kyron.bio announced the successful closing of a $6.2M (€5.5M) seed funding round aimed at solving critical challenges in biologic drug development, specifically varying efficacy and the dangers of side effects.
- The round was led by HCVC, with participation from Verve Ventures, Entrepreneurs First, Saras Capital, and numerous reputable angel investors.
- The funds will be used to accelerate the development of kyron.bio’s proprietary
Read More
Brooklyn Health Secures $6.5M to Expand AI-Powered Precision for Clinical Trial Endpoints
What You Should Know:
- Brooklyn Health, a neuroscience technology company focused on objective measurement of mental health announced it has secured $6.5M in seed funding led by HealthX, with participation from Metrodora Ventures, Story Ventures, RiverPark Ventures, Laconia Capital, Everywhere Ventures, Hypothesis Studio, Blue Falcon Capital, and others.
- The funding coincides with the company's debut of its new electronic clinical outcome assessment (eCOA) solution, Willis. Willis
Read More
Key Features to Look for in a Microplate Luminometer
Microplate luminometers play a critical role in luminescence-based assays, powering applications ranging from cell signaling studies to high-throughput drug screening. With a wide variety of models available on the market, selecting the right instrument means ensuring it includes the essential features that will deliver reliable, sensitive, and reproducible results. Below are the key features to prioritize when choosing a microplate luminometer:
1. Luminescence Sensitivity
Sensitivity is
Read More
Biostate AI Secures $12M to Optimize RNA Sequencing, Precision Medicine
What You Should Know:
- Biostate AI, an innovator at the intersection of artificial intelligence and RNA sequencing raises $12M in Series A funding spearheaded by Accel, with participation from Gaingels, Mana Ventures, InfoEdge Ventures, and existing investors Matter Venture Partners, Vision Plus Capital, and Catapult Ventures. This brings the company's total funding to over $20M.
- The newly acquired funds will be pivotal in advancing Biostate AI’s mission to unlock affordable and
Read More
Cycle Time is the New Currency of Drug Development
For years, the life sciences industry has been trying to address the same R&D challenges: rising costs, patient recruitment and retention, and difficulty maximizing ROI. Drug development is expensive, and failure rates remain high. Studies estimate the total cost to develop a new drug is between $300 million and nearly $4.5 billion. Meanwhile, clinical trial cycle times continue to lengthen – significantly impacting overall drug development timelines. Clinical trials are increasingly
Read More
Closing the Affordability Gap: How Automation is Advancing Biosimilar Adoption
Millions of Americans are currently facing a difficult choice: either pay for expensive biologic medications or ration doses to afford basic needs. Cost-related nonadherence (CRN) is where patients either skip or delay their medication due to cost concerns, a challenge that is widespread throughout the U.S. The financial burden is even greater for those managing multiple chronic conditions, where prescription costs can quickly add up to unmanageable amounts.
Despite the financial strain,
Read More
PhaseV Closes $50M to Advance AI Clinical Development
What You Should Know:
- PhaseV, a company at the forefront of applying artificial intelligence (AI) and machine learning (ML) to clinical development raies $50M in Series A funding round co-led by Accel and Insight Partners, with participation from existing investors Viola Ventures, EXOR, and LionBird. This round brings PhaseV's total funding to date to $65M.
- The new capital is earmarked to fuel PhaseV’s mission to support pharmaceutical companies, biotech firms, and contract
Read More
